Navigation Links
Refrigerated Stem Cells Survive 12 Times Longer with ProtoKinetix's,AAGP

VANCOUVER, British Columbia--(BUSINESS WIRE)--Jun 7, 2007 - As a follow up to ProtoKinetix Inc.'s (OTCBB:PKTX) May 23, 2007 press release related to cryopreserved (or frozen) cells treated with AAGP(TM), in collaboration with the University of Helsinki, Finland, ProtoKinetix has recently finished a set of trials designed to determine whether AAGP(TM) treated cells could survive after preservation in refrigeration (4 degrees C).

Commenting on the results, ProtoKinetix's Director of Scientific Affairs, Dr. John Todd, stated, "After 3 days of preservation in refrigeration, untreated stem cells have a very high mortality rate. In the most recent experiments with the University of Helsinki, Finland, it was determined that AAGP(TM) can significantly reduce this cell death rate. AAGP(TM) demonstrated an impressive and repetitive 8 to 12 times increase in cell viability and survivability."

Dr. Todd added, "These results are extremely important and encouraging for isolating the limited stem cell populations found in certain organs and tissues, such as umbilical cord blood and bone marrow. The implications for the treatment of certain types of cancers, such as leukemia and other conditions requiring bone marrow transplant are enormous."

For further information, investors are asked to visit the ProtoKinetix Investor Relations Hub at www.agoracom.com/IR/ProtoKinetix or email to PKTX@agoracom.com.

About ProtoKinetix:

ProtoKinetix Inc. is a Biotechnical Company dedicated to the development of a family of synthetic antifreeze glycoproteins (AAGP(TM)) for human and veterinary medicine, the biotechnology and cosmetic industries. Using previously published research on native antifreeze proteins and antifreeze glycoproteins as a guide, and coordinating a vast pool of world recognized intellectual talent in a networked environment, PKTX is conducting rapid and meaningful research with a view to developi ng markets for this very useful family of molecules. Sign up for free automatic email news alerts at our new website at: www.protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission at www.sec.gov.

On behalf of the Board of Directors

Company Office:

Suite # 1500

885 West Georgia Street

Vancouver, BC V6C 3E8

Contact

ProtoKinetix Inc.
Blair Henderson, 604-687-9887


'"/>




Related medicine technology :

1. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
2. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
3. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
4. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
5. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
6. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
7. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
8. Pluristems PLX Cells Demonstrate Potential to Treat Parkinsons Disease
9. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
10. ProtoKinetixs AAGP Dramatically Increases Recovery Rate of Cryopreserved Stem Cells
11. AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin Cells Have the Ability to Recognize, Transport and Utilize L-ergothioneine (EGT) As A Protector Against Oxidative Damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Summary This report provides all the information ... interests and activities since 2010. Description The Partnering Deals ... the partnering activity of one of the world,s leading life ... upon purchase to ensure inclusion of the most up to ... be delivered in PDF format within 1 working day of ...
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immunotherapy successfully passed early toxicology and efficacy studies. The ... to target a specific protein, MAGE A, in an ... breast cancer. After 4 weeks of ... to show very little toxicity in a full toxicology ...
(Date:3/27/2017)... Germany , March 27, 2017 ... over 7,000 attendees and more than 600 exhibitors ... and discover opportunities and solutions that will advance ... 6 April 2017 at the Messe Stuttgart, ... the preeminent medical technology platform showcasing the key ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... ... the science and clinical practice of radiosurgery, announced today the publication of ... observational registry established to standardize data collection from patients treated with stereotactic ...
(Date:3/28/2017)... ... , ... Usually, the impending arrival of warmer weather means the gleeful banishment ... double chin, this means more anxiety than elation. The cosmetic dermatology experts at Cosmetic ... double chin is undesirable,” Dr. Goldman said, “but it seems doubly so when the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology , a ... time and attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service ... uses biometric face recognition to enable users to check in and out from ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder ... few medical professionals in the country to sit on the 2017 National Advisory Board ... just 2 years Dr. Harper helped propel the clinic from a small start-up to ...
(Date:3/28/2017)... ... 28, 2017 , ... The Lice Treatment Center® booth at ... was a busy spot this year. Liz Solovay and Adrian Picheny, the firm’s ... among camp communities during the upcoming 2017 camping season. “Lice infestations at some ...
Breaking Medicine News(10 mins):